Tower Research Capital (TRC)’s Opiant Pharmaceuticals, Inc. Common Stock OPNT Stock Holding History

Tower Research Capital (TRC)’s Portfolio OPNT Stock Details OPNT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-744	Closed	-$15K	–	6675
2022 Q4	$15K	Buy	744 +310	+71%	+$4.75K	﹤0.01%	3473
2022 Q3	$4K	Sell	434 -935	-68%	-$10.6K	﹤0.01%	5335
2022 Q2	$16K	Buy	1,369 +1,215	+789%	+$19.6K	﹤0.01%	4043
2022 Q1	$3K	Buy	+154	New	+$4.08K	﹤0.01%	5475
2021 Q4	–	Sell	-138	Closed	-$4K	–	6848
2021 Q3	$4K	Sell	138 -120	-47%	-$2.15K	﹤0.01%	5040
2021 Q2	$3K	Sell	258 -25	-9%	-$309	﹤0.01%	4985
2021 Q1	$3K	Sell	283 -633	-69%	-$7.22K	﹤0.01%	4952
2020 Q4	$7K	Buy	916 +597	+187%	+$4.7K	﹤0.01%	4517
2020 Q3	$3K	Sell	319 -3,408	-91%	-$30.3K	﹤0.01%	4542
2020 Q2	$34K	Buy	+3,727	New	+$38.7K	﹤0.01%	3369

Tower Research Capital (TRC)'s OPNT Position: Q1 2023 in Review

Tower Research Capital (TRC) sold out of Opiant Pharmaceuticals, Inc. Common Stock (OPNT) in Q1 2023, closing a stake of 744 shares — an estimated $15K sold.

Tower Research Capital (TRC) first reported a position in OPNT in Q2 2020 and held it in 10 quarters. The position peaked at $34K in Q2 2020. 0 funds tracked by Wall St. Rank hold OPNT as of Q1 2023.

Tower Research Capital (TRC) reported no remaining Opiant Pharmaceuticals, Inc. Common Stock position as of Q1 2023 after selling out during the quarter.
Tower Research Capital (TRC) sold 744 Opiant Pharmaceuticals, Inc. Common Stock shares in Q1 2023, an estimated $15K.
Tower Research Capital (TRC) first reported a position in Opiant Pharmaceuticals, Inc. Common Stock in Q2 2020 and held it in 10 quarters.
Tower Research Capital (TRC)'s Opiant Pharmaceuticals, Inc. Common Stock position peaked at $34K in Q2 2020.
0 funds tracked by Wall St. Rank held Opiant Pharmaceuticals, Inc. Common Stock as of Q1 2023.

Based on Tower Research Capital (TRC)'s 13F filing for Q1 2023, filed 9 May 2023.